Fly News Breaks for January 30, 2020
Jan 30, 2020 | 05:28 EDT
Piper Sandler analyst William Quirk raised his price target for Hologic to $61 from $58 following the company's fiscal Q1 results and keeps an Overweight rating on the shares. . Management lowered reported fiscal 2020 guidance following the CynoSure divestiture, and reiterated their confidence in the core business, Quirk tells investors in a post-earnings research note. He believes the divestiture will enable management to "substantially" grow margins and keeps an Overweight rating on Hologic shares.
News For HOLX From the Last 2 Days
There are no results for your query HOLX